Orcosa Appoints Andy Drechsler as Chief Financial Officer
Orcosa
  • Technology
    Technology
    • RITe™ Platform

      Our breakthrough, proprietary technology platform engineered to enhance drug absorption

    • Capabilities

      End-to-end, in-house control of formulation, development, and manufacturing capabilities

  • Research
    Research
    • ORC-144 Research + Development

      Our proprietary cannabinoid composition for the management of pain and inflammation

    • Research Partners

      Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials

    • About Cannabidiol

      Learn more about cannabidiol from the medical community and regulators

  • Company
    Company
    • About Us

      We are modernizing the way medicines are taken

    • Our Team

      Experts in drug development and delivery, manufacturing, and commercialization

  • News
    News
    • In the News

      Recent media coverage regarding Orcosa

    • Press Releases and Blog Posts

      Company news and announcements

  • Careers
    Careers
Contact

Press Releases
and Blog Posts

Mar 25, 2022
Orcosa Comments on Positive Results of NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORC-144
Mar 17, 2022
Orcosa Announces Results from Leading Phase 1/2 Clinical Trial Utilizing ORC-144 to be Presented at American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting
Dec 27, 2021
Statement on Final Patient Dosing in NYU Langone Health’s Phase 1/2 Clinical Trial Utilizing ORC-144
Nov 08, 2021
Statement of Congratulations to Dr. Michael J. Alaia of NYU Langone Health Orthopedic Hospital for Best Paper Award at the 2021 Sir Robert Jones Alumni Scientific Program
« Previous 1 2 3 4 5 Next »
  • Technology
  • Research
  • Company
  • Careers
Orcosa
© 2025 Orcosa. All rights reserved.
  • Privacy Policy
  • Accessibility Statement